Ongoing excellent outcomes with reduced toxicities following integration of molecular targeted therapies in pediatric anaplastic large cell lymphoma.

Anaplastic large cell lymphoma (ALCL) accounts for 10–15% of pediatric and adolescent lymphomas [1]. ALCL is a T or null cell lymphoma characterized by malignant expression of CD30 [2]. The majorit...